Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 158.00p 154.00p 162.00p - - - 0 05:30:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 1.9 -52.4 9.6 15.5 446.63

Puretech Share Discussion Threads

Showing 226 to 249 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
19/8/2018
16:50
Tipped over the weekend http://www.dailymail.co.uk/money/investing/article-6075995/SUNDAY-NEWSPAPER-SHARE-TIPS-Drax-PureTech-investment-trusts-tilted-overseas-stocks.html
countless
10/8/2018
03:02
And more good news from last week: 2 August 2018 PureTech Health plc PureTech's Karuna Completes $42 Million Financing Round to Advance Lead Product Candidate for the Treatment of Disorders Marked by Psychosis and Cognitive Impairment PureTech Health plc (LSE: PRTC) ("PureTech Health"), a clinical-stage biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG), today announced that its affiliate, Karuna, successfully completed a $42 million Series A financing round, including the issuance of $22 million in shares upon conversion of debt into equity. This financing round included ARCH Venture Partners, the Wellcome Trust, Steven Paul MD, PureTech Health, and other undisclosed investors. Proceeds from the financing will be used to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the initiation of a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas, including a non-opiate pain indication. Joep Muijrers, PhD, Chief Financial Officer at PureTech Health, said: "The financial commitment from these high-profile investors shows clear confidence in Karuna's approach to developing what could be the first new mechanism in over 50 years for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders. As KarXT advances into a Phase 2 trial, we believe strongly in Karuna's unique mechanism of action and potential."
rambutan2
10/8/2018
03:00
Good news from yesterday: PureTech's Akili Expands Series C Funding, Increasing Round to $68 Million, with $13 Million in New Investments New Investors Include CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures PureTech Health plc (LSE: PRTC) ("PureTech Health"), a clinical-stage biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG), today announced that its independent affiliate, Akili, has raised $13 million in new funding as an extension of its recent Series C financing. The Series C extension brings the total equity financing Akili has raised this year to $68 million. Participating investors include CLSA, Omidyar Technology Ventures, Digital Garage Group, and Fearless Ventures. Akili's initial Series C financing round was led by Temasek and included additional investors Baillie Gifford, Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. Akili will use the funds to further advance development and deployment of its pipeline of prescription digital treatment candidates, including its lead product candidate, AKL-T01, through key regulatory milestones and commercial preparations. Akili also plans to use the funds to advance a number of other digital treatments in development, including Major Depressive Disorder ("MDD"), multiple sclerosis ("MS") and various other inflammatory diseases. Bharatt Chowrira, PhD, President and Chief of Business and Strategy at PureTech Health, said: "This financing is an additional validation for Akili and further augments their strong cash position as they progress on their path to offer potentially safe, effective, and personalised digital treatments for patients across a range of mental health and neurological conditions."
rambutan2
26/7/2018
15:18
wow - if restorbio goes back to ten bucks i will buy some stateside. apparently lock in expires next week...
edwardt
25/7/2018
14:53
come off a chunk now stateside. interesting to see where it finishes!
edwardt
25/7/2018
13:49
i tried to buy prtc and was only offered 1000. the rise will come but it will lag.
edwardt
25/7/2018
13:48
you are spot on chap. i am pretty sure they have not sold any.
edwardt
25/7/2018
13:39
ResTORbio (NASDAQ: TORC) up 164% in pre-trading as of now. That's a marcap uplift of around $414m. PRTC own 34.9%, so adds $414x0.349/1.31 = approx £110m to the value of their holding. This equates to £110m/282.68m = 38.9p per share. Or have I got my maths wrong, as the market reaction certainly suggests? (Pre-trading price dropping a little as I type, but still...)
elgordo
25/7/2018
13:10
restorbio going mental state side!
edwardt
22/7/2018
21:35
Watch PureTech Health (PRTC) closely on potential $1B+ deal http://crweworld.com/article/news-provided-by-business-wire/743450/puretech-health-announces-collaboration-with-roche-to-advance-technology-for-oral-administration-of-antisense-oligonucleotides
danieldanj
20/7/2018
13:15
Always has done but agree a promise of up to a billion in funding should get mr markets attention
edwardt
20/7/2018
07:05
This looks interesting now
mirabeau
16/7/2018
14:04
lets hope so. as much as i like help save the world, it would be nice to get rich along the way too.
edwardt
12/7/2018
17:37
I agree, it feels like this is under the radar - which is fine by me as it helps accumulate a holding. However with cash balances of more than a third of the mcap and the sheer brilliance of the minds at work in this firm with the pipeline and partnerships, it won't be long before this will race past broker targets of £3.
jthomas10
12/7/2018
15:03
Very encouraging news, I purchased a few more here this week, well below ipo and share issue prices of course, I expect that at some stage this year there will be sufficient newsflow to really move the share price closer to the brokers targets of circa £3
lendmeafiver
12/7/2018
09:15
i would have thought these figures are pretty impressive indeed! shares up 10% stateside. anyone care to comment either way. he incidence of infections was assessed for one year after initiation of study drug treatment. In the RTB101 monotherapy and RTB101+everolimus combination treatment arms, statistically significant and clinically meaningful reductions in the annual rate of infections of 33% (p=0.008) and 38% (p=0.001), respectively, compared to placebo, were observed. In addition, both RTB101 monotherapy and the RTB101+everolimus combination therapy were observed to reduce the incidence of RTIs at one year by 42% (p=0.006) and 36% (p=0.01), respectively.
edwardt
30/6/2018
13:50
An interesting read about Vedanta Biosciences, which is part of the PureTech Group, and what it is doing with microbiome therapies which seem to be coming to fruition. hxxps://www.bostonglobe.com/business/2018/06/18/microbiome/4qkHpemmUCWcNVO1ERuIyH/story.html
countless
29/6/2018
18:17
Recent presentation from TORC: htTP://ir.restorbio.com/static-files/4736a867-ea3a-4205-851c-658783690277 I was wondering what everolimus is: httPS://about-cancer.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/everolimus httPs://www.novartis.co.uk/news/media-releases/nice-publishes-recommendation-novartis-drug-afinitorr-everolimus-its-final-draft
rambutan2
14/6/2018
22:11
What's with today's 800k volume?
saleen230
06/6/2018
16:03
impressive hires at gelesis
edwardt
01/6/2018
11:01
lets hope some buying follows yesterday's presentations.. market makers are moving the offer around..
edwardt
29/5/2018
11:02
looking at shareholders;_ IP own 27% (he has also backed some of the raises for the underlying companies. Lansdowne own 8% they a top hedge fund in my opinion. BG who are good growth managers own 6% jupiter 4.6% this is brother of lansdowne main man. he tends to shadow trade his big bro! zohar owns 4.6% herself so she has good skin in the game
edwardt
25/5/2018
12:24
nice option award for the cfo!
edwardt
09/5/2018
16:56
restorbio = also finding a floor in the states. i wish i had a bit more cash...
edwardt
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180820 06:49:41